Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are often present in newly
diagnosed acute myeloid leukemia (AML) patients with an incidence rate of approximately …

Introduction: Activating mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur at
high frequency in acute myeloid leukemia (AML), being detected in> 30% of patients at …

Mutations in the fms-like tyrosine kinase 3 (FLT3) gene are detected in approximately one-
third of patients with newly diagnosed acute myeloid leukemia (AML). These consist of the …

Acute myeloid leukemia (AML) is a cancer of the myeloid lineage of blood cells. Although
significant progress has been made in treating many types of cancers during recent years …

Fms-like tyrosine kinase 3 (FLT3) is the most frequently mutated gene in acute myeloid
leukemia (AML). Modern targeting of FLT3 with inhibitors has improved clinical outcomes …

The receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3), involved in regulating
survival, proliferation, and differentiation of hematopoietic stem/progenitor cells, is …

The FMS-like tyrosine kinase 3 (FLT3) pathway has an important role in cellular proliferation,
survival, and differentiation. Acute myeloid leukemia (AML) patients with mutated FLT3 have …

FMS‐like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase that plays an
important role in hematopoietic cell survival, proliferation and differentiation. The most …

Abstract Since the Food and Drug Administration approval of imatinib for treatment of
chronic myeloid leukemia in 2001, tyrosine kinase inhibitors (TKIs) have become a mainstay …

Small-molecule FLT3 inhibitors have recently improved clinical outcomes for patients with
FLT3-mutant acute myeloid leukemia (AML) after many years of development, but resistance …